ArticleAmerican journal of translational research2025
Rare esophageal large-cell neuroendocrine carcinoma treated with Serplulimab: a case report.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Esophageal Large-cell Neuroendocrine Carcinoma With Pagetoid Spread: A Case Report and Literature Review.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal large-cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive malignancy that presents diagnostic and therapeutic challenges. We present the case of a 72-year-old female with LCNEC of the distal esophagus who was initially treated with chemotherapy and radiation therapy, followed by immunotherapy due to disease progression. Diagnostic imaging revealed extensive metastases to the abdominal lymph nodes. Histopathological examination confirmed the diagnosis of LCNEC with high-grade squamous intraepithelial neoplasia. The treatment complexities underscore the necessity of a multidisciplinary approach involving medical oncologists, radiation oncologists, and pathologists. While chemotherapy remains the standard, the role of immunotherapies, such as Slurilizumab in LCNEC management is evolving. Subsequent imaging revealed gradual tumor reduction, and the patient was maintained on immunotherapy. The patient has remained on immunotherapy since then, with a progression-free survival of 1 year and 4 months as of the latest follow-up, approximately 3 years post-diagnosis. This case highlights the potential of combining immunotherapy with conventional treatments for disease control. Further research is crucial to optimizing therapeutic strategies and prognostic factors for esophageal LCNEC to enhance clinical outcomes and patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.